IS3865A - Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina - Google Patents

Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina

Info

Publication number
IS3865A
IS3865A IS3865A IS3865A IS3865A IS 3865 A IS3865 A IS 3865A IS 3865 A IS3865 A IS 3865A IS 3865 A IS3865 A IS 3865A IS 3865 A IS3865 A IS 3865A
Authority
IS
Iceland
Prior art keywords
intermediates
production
analogous method
benzofuran derivatives
benzofuran
Prior art date
Application number
IS3865A
Other languages
English (en)
Other versions
IS1609B (is
Inventor
Clive Ross Barry
Middlemiss David
Ian Carter Scopes David
Iain Mclean Jack Torquil
Stuart Cardwell Kevin
Dennis Dowle Michael
Bruce Judd Duncan
Paul Watson Stephen
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS3865A publication Critical patent/IS3865A/is
Publication of IS1609B publication Critical patent/IS1609B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS3865A 1991-05-16 1992-05-15 Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina IS1609B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110636A GB9110636D0 (en) 1991-05-16 1991-05-16 Chemical compounds

Publications (2)

Publication Number Publication Date
IS3865A true IS3865A (is) 1992-11-17
IS1609B IS1609B (is) 1996-10-18

Family

ID=10695121

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3865A IS1609B (is) 1991-05-16 1992-05-15 Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina

Country Status (21)

Country Link
US (2) US5332831A (is)
EP (1) EP0514198B1 (is)
JP (1) JPH06211846A (is)
KR (1) KR920021541A (is)
AP (1) AP318A (is)
AT (1) ATE169297T1 (is)
AU (2) AU1692692A (is)
BG (1) BG98216A (is)
CA (1) CA2068766A1 (is)
CZ (1) CZ243093A3 (is)
DE (1) DE69226472D1 (is)
FI (1) FI935036A0 (is)
GB (1) GB9110636D0 (is)
IL (1) IL101882A0 (is)
IS (1) IS1609B (is)
MX (1) MX9202281A (is)
NO (1) NO921944L (is)
OA (1) OA09841A (is)
SK (1) SK112893A3 (is)
TW (1) TW221998B (is)
WO (1) WO1992020674A1 (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
US5336779A (en) * 1992-10-08 1994-08-09 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Method of producing formylimidazoles
CA2232663C (en) * 1995-10-06 2008-04-08 Novartis Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
JP4369994B2 (ja) 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト
KR100567183B1 (ko) * 1997-11-14 2006-06-13 론자 아게 포르밀이미다졸의제조방법
ATE354364T1 (de) 1998-12-23 2007-03-15 Novartis Pharma Gmbh Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
EP1197226B1 (en) * 1999-07-21 2007-11-21 Takeda Pharmaceutical Company Limited Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
WO2002013821A1 (en) * 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
JP5498781B2 (ja) * 2006-05-05 2014-05-21 ダウ グローバル テクノロジーズ エルエルシー 複素環式有機リガンドのハフニウム錯体
WO2008029825A1 (fr) 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Dérivé d'imidazole
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP5072675B2 (ja) 2007-04-03 2012-11-14 四国化成工業株式会社 2−ハロイミダゾール化合物の製造方法
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
CA3067918A1 (en) 2017-07-07 2019-01-10 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats
CN110256382A (zh) * 2019-06-06 2019-09-20 武汉药明康德新药开发有限公司 一种2-(5-甲基苯并呋喃-2-基)苯甲腈的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1389827A (en) * 1971-07-23 1975-04-09 Fisons Ltd Tetrazolyl benzopyrans
JPS54148788A (en) * 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
ZA824343B (en) * 1981-07-01 1983-04-27 Upjohn Co Pyridinyl- and imidazolyl-benzofurane and benzothiophenes
JPS6163671A (ja) * 1984-09-05 1986-04-01 Shionogi & Co Ltd 2,3−ジヒドロベンゾフラン−5−スルホンアミド誘導体および降圧利尿剤
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
SG52330A1 (en) * 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
DE69025473T2 (de) * 1989-06-30 1996-10-17 Du Pont Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
AU645022B2 (en) * 1989-06-30 1994-01-06 E.I. Du Pont De Nemours And Company Fused-ring aryl substituted imidazoles
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
HUT67014A (en) * 1991-05-16 1995-01-30 Glaxo Group Ltd Benzofuran derivatives, pharmaceutical compositions containing them and process for the preparation of thereof
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane

Also Published As

Publication number Publication date
WO1992020674A1 (en) 1992-11-26
US5498722A (en) 1996-03-12
IS1609B (is) 1996-10-18
KR920021541A (ko) 1992-12-18
GB9110636D0 (en) 1991-07-03
AU1632192A (en) 1993-03-11
FI935036A (fi) 1993-11-15
MX9202281A (es) 1992-11-01
AU654350B2 (en) 1994-11-03
ATE169297T1 (de) 1998-08-15
CZ243093A3 (en) 1994-03-16
SK112893A3 (en) 1994-11-09
EP0514198A1 (en) 1992-11-19
AP318A (en) 1994-02-15
BG98216A (en) 1994-08-15
NO921944L (no) 1992-11-17
EP0514198B1 (en) 1998-08-05
OA09841A (en) 1994-08-15
NO921944D0 (no) 1992-05-15
JPH06211846A (ja) 1994-08-02
AU1692692A (en) 1992-12-30
CA2068766A1 (en) 1992-11-17
US5332831A (en) 1994-07-26
DE69226472D1 (de) 1998-09-10
IL101882A0 (en) 1992-12-30
TW221998B (is) 1994-04-01
FI935036A0 (fi) 1993-11-15

Similar Documents

Publication Publication Date Title
IS1609B (is) Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina
IS1713B (is) Hliðstæð aðferð til framleiðslu á andróstenón afleiðu og milliefni til notkunar með aðferðinni
IS3915A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3914A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3873A (is) Hliðstæð aðferð til framleiðslu á kristölluðum oxaþíólan afleiðum
IS3994A (is) Hliðstæð aðferð til framleiðslu á indole afleiðum
DK451187D0 (da) Fremgangsmaade og apparat til kraftproduktion
NO177084C (no) Fremgangsmåte og anordning for kontinuerlig fremstilling av absorbente legemer
IS3936A (is) Hliðstæð aðferð til framleiðslu á vatnsuppleysanlegum kamptóþesín afleiðum
NO305634B1 (no) FremgangsmÕte og anordning for kake-produksjon
IS3823A (is) Ný carboxyl-amid efnasambönd og aðferð til framleiðslu þeirra
NO950412D0 (no) Fremgangsmåte og apparat for fremstilling av tremel, samt anvendelse derav til fremstilling av plater
IS3954A (is) Hliðstæð aðferð við framleiðslu nýrra peptíðafleiða
NO885006L (no) Fremgangsmaate og anordning for bevegelseskompensering av stigeroer.
NO176425C (no) Fremgangsmåte og anordning til kontinuerlig utglödning av amorfe bånd i produksjonslinjen
IS3718A7 (is) Amínóbenzodiazepines og aðferð til framleiðslu þess
IS4012A (is) Tæki til að framleiða vinnslumiðil fyrir orkuver,einkum raforkuver, og aðferð til framleiðslu á áðurnefndum vinnslumiðli
IS4244A (is) Aðferð til framleiðslu á Indoline afleiðum og notkun þeirra
IS3555A7 (is) Pyrrol-afleiður og aðferð til framleiðslu þeirra
IS3857A (is) Karboxýl-sýruafleiður og aðferð til framleiðslu þeirra
IS3827A (is) Hliðstæð aðferð við framleiðslu á pýrról[2,3 b]pýridínum
DK0635004T3 (da) 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
IS3969A (is) Hliðstæðar aðferðir til framleiðslu á bensópýran og skyldum LTB4 mótlyfjum
IS4980A (is) Aðferðir og milliefni við framleiðslu á setnum krómanól afleiðum
NO174334C (no) Fremgangsmåte og innretning til fremstilling av fiberplater